Ryszard Kole
Kole, Ryszard
VIAF ID: 315225519 (Personal)
Permalink: http://viaf.org/viaf/315225519
Preferred Forms
-
100 1 _ ‡a Kole, Ryszard
-
100 1 _
‡a
Kole, Ryszard
-
100 0 _
‡a
Ryszard Kole
4xx's: Alternate Name Forms (3)
Works
| Title | Sources |
|---|---|
| Abstracts of papers presented at the 2010 meeting on RNA & oligonucleotide therapeutics, 2010: |
|
| Analysis of prostate-specific membrane antigen splice variants in LNCap cells |
|
| Applications of the PMO platform to genetic diseases. |
|
| Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents |
|
| Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy |
|
| Effects of base modifications on antisense properties of 2'-O-methoxyethyl and PNA oligonucleotides |
|
| Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study |
|
| High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA. |
|
| HIV-1 preferentially binds receptors copatched with cell-surface elastase |
|
| The importance of Bcl-xL in the survival of human RPE cells |
|
| Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers |
|
| Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching |
|
| Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells |
|
| Oligorewolucja |
|
| Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy |
|
| Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping |
|
| Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder |
|
| Restoration of correct β-globin mRNA splicing and HbA production by engineered U7 snRNA in β-thalassaemia/HbE erythroid cells |
|
| Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. |
|
| RNA modulation, repair and remodeling by splice switching oligonucleotides |
|
| Self-aggregating 1.8kDa polyethylenimines with dissolution switch at endosomal acidic pH are delivery carriers for plasmid DNA, mRNA, siRNA and exon-skipping oligonucleotides. |
|
| Short-term and long-term modulation of gene expression by antisense therapeutics |
|
| Size-uniform 200 nm particles: fabrication and application to magnetofection |
|
| Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. |
|
| Splicing: hear and now! |
|
| Superoxide-dependent iron uptake: a new role for anion exchange protein 2. |
|
| Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. |
|
| Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking oligonucleotides |
|
| Targeted correction of a thalassemia-associated beta-globin mutation induced by pseudo-complementary peptide nucleic acids |
|
| Targeted exon skipping to address "leaky" mutations in the dystrophin gene. |
|
| Targeting mRNA splicing as a potential treatment for Duchenne muscular dystrophy |
|
| Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing |
|
| Znokautowane myszy pomagają w rozwikłaniu tajemnicy genów : Nagroda Nobla 2007 : Medycyna i Fizjologia |
|
